Actively Recruiting
A Trial Comparing the Effectiveness and Tolerability of Medications in Older Adults With Stable Angina and Multiple Chronic Conditions: LIVEBETTER
Led by Yale University · Updated on 2026-04-07
741
Participants Needed
10
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness and tolerability of standard anti-anginal medications, specifically beta-blockers and calcium channel blockers, in older adults who have symptomatic Stable Ischemic Heart Disease (SIHD) along with multiple chronic conditions (MCC). This pragmatic, single-blind, randomized trial aims to fill gaps in current guidelines by comparing these treatments in terms of symptom relief, function, quality of life, and safety. The study also explores caregiver burden and cognitive outcomes as part of an ancillary neurocognitive study. Participants are randomly assigned to receive either beta-blocker or calcium channel blocker therapy, with the choice and dosing of specific drugs determined by their treating clinicians following clinical guidelines. Both treatments are administered orally in pill form. The main study includes four visits over 12 months involving interviews, a six-minute walk test, and medical record reviews. An ancillary neurocognitive study extends follow-up to 24 months to assess cognitive decline and incidence of mild cognitive impairment or dementia. During the study, participants will undergo assessments such as quality of life surveys using EQ-5D-5L and PROMIS Scale, angina control evaluations with the Seattle Angina Questionnaire, and caregiver burden inventories. Physical function is measured by a six-minute walk test. Medication adherence and persistence will be monitored up to six months. Safety and tolerability are evaluated throughout, with follow-up visits scheduled to track long-term outcomes related to both heart and cognitive health.
CONDITIONS
Brief Title
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 years or older
- Diagnosis of symptomatic stable ischemic heart disease with plans to start medical therapy
- At least 2 multiple chronic conditions as defined by CMS
- Positive non-invasive or invasive testing indicating coronary artery disease
- Caregivers aged 18 years or older identified by participant
You will not qualify if you...
- Currently taking both a beta-blocker and a calcium channel blocker
- Contraindications to beta-blockers or calcium channel blockers such as significant hypotension, high-grade AV block, severe symptomatic bradycardia, or severe obstructive lung disease
- Documented intolerance to beta-blockers or calcium channel blockers
- High-risk coronary artery disease needing immediate revascularization
- Plans for complete revascularization within 2 weeks
- Clear clinical indication for beta-blockers or calcium channel blockers that prevents dose adjustment
- Participation in another clinical trial involving investigational medication or device
- Primary language other than English or Spanish
- Inability to complete follow-up (e.g., life expectancy less than 12 months or impaired decision-making)
- Previous enrollment in LIVEBETTER
- Refusal of informed consent
- Caregivers who are professional (not relatives or close friends)
- Caregivers not speaking English or Spanish
- Caregivers unable to complete follow-up
- Caregivers previously enrolled or who refuse consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants receive either beta-blocker or calcium channel blocker therapy as prescribed by their clinician. Medication dose and administration are managed as part of routine clinical care.
4 study visits during the 12-month follow-up period
Duration - Up to 24 months
Participants enrolled in the ancillary neurocognitive study will have extended follow-up to assess cognitive function and other outcomes.
Additional visits as part of the extended neurocognitive follow-up
Trial Site Locations
Total: 10 locations
1
Yale School of Medicine
New Haven, Connecticut, United States, 06520
Actively Recruiting
2
Wellstar Research Institute
Marietta, Georgia, United States, 30060
Actively Recruiting
3
Cook County Health
Chicago, Illinois, United States, 60612
Actively Recruiting
4
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
5
Mt. Sinai Health System
New York, New York, United States, 10029
Actively Recruiting
6
NYC Health and Hospitals, Harlem Hospital
New York, New York, United States, 10037-1802
Not Yet Recruiting
7
Nirvana Integrative Medicine
New York, New York, United States, 10469
Actively Recruiting
8
Duke University, School of Medicine
Durham, North Carolina, United States, 27710
Actively Recruiting
9
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Not Yet Recruiting
10
Inova Health Care Services
Fairfax, Virginia, United States, 22033
Actively Recruiting
Research Team
M
Michael Nanna, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here